Objective: Tricuspid valve replacement (TVR) has a high postoperative mortality, despite recent advances in perioperative care. We report the results of our experience in TVR with an emphasis on early mortality and morbidity and long-term follow-up. Methods: Between October 1994 and August 2007, 80 consecutive TVRs were performed in 78 patients. The mean age was 48 AE 14 (range: 20-70) years. The underlying disease of the patients was classified as rheumatic (n = 54), congenital (n = 12), endocarditis (n = 10) or degenerative (n = 4). Previous cardiac surgery had been performed in 40 patients (50%). Isolated TVR was performed in 24 patients (30%). Results: Hospital mortality occurred in one patient (1.4%). Postoperative morbidities included intra-aortic balloon pump (n = 5), bleeding re-operation (n = 4), delayed sternal closure (n = 3), acute renal failure (n = 3), subdural haematoma (n = 3), extracorporeal membrane oxygenation (n = 1), mediastinitis (n = 1) and pacemaker insertion (n = 4). In 42 patients, ventilator support was needed for more than 72 h. Based on multivariate analysis, age ( p < 0.001) and the cardiopulmonary time ( p = 0.004) were the identified risk factors. Follow-up was completed in all patients with a mean duration of 56 AE 37 (range: 0-158) months. During the follow-up period, there were seven deaths (8.8%), including five cardiac deaths. The 5-and 8-year survival rates were 95 AE 3% and 79 AE 9% and event-free survival rates were 76 AE 6% and 61 AE 9%, respectively. Based on multivariate analysis, the only identified predictors of late deaths was a postoperative low cardiac output ( p = 0.024). Conclusions: TVR can be performed and low operative mortality can be achieved thorough optimal perioperative management in the current era. #
Introduction
Tricuspid valve replacement (TVR) is an uncommon procedure, because the prevalence of clinically significant tricuspid valve disease is rare and usually amenable to repair. Historically, the operative mortality associated with TVR in the literature is very high (5-50%) [1] [2] [3] [4] . During the last three decades, the early mortality and morbidity after cardiac valve surgery has been reduced because of improvements in myocardial protection and postoperative care [5, 6] . However, recent studies involving TVR have reported very high operative mortality rates [1, 3, 4] . With this background in mind, we have evaluated the early results of a consecutive series of patients undergoing TVR in a single institution to determine the outcome of TVR in the current era.
Materials and methods
We retrospectively reviewed data on 78 consecutive patients who underwent TVR at the Samsung Medical Center between October 1994 and August 2007. In two patients, TVR was performed twice in the study period, so the total number of TVRs was 80. All the other patients who underwent TVR, either as an isolated procedure or in combination with other procedures, were included. During the study period, valve repair (n = 663) was the preferential procedure for all tricuspid valve diseases. Approval was obtained from our institution's Research Ethics Board to review our database and clinical records.
Patient characteristics
The patient demographics are presented in Table 1 . The underlying diseases of the patients included rheumatic (n = 54), congenital (n = 12), endocarditis (n = 10) or degenerative (n = 4). Previous cardiac surgery had been performed in 40 patients (50.0%). Twenty-three patients had previous tricuspid valve surgery (repair (n = 19) or replacement (n = 4)).
Surgical technique
A midline sternotomy was performed in all patients, except one in whom a right anterolateral thoracotomy was performed. Standard aortic and direct bicaval cannulations were performed in 70 patients. Femoral artery and venous cannulations were used in 10 patients. With the exception of three patients in whom tricuspid replacement was performed under a beating heart, myocardial protection was achieved by antegrade or retrograde cold-blood cardioplegia infusions.
In 56 patients, concomitant valve procedures or coronary artery bypass grafting was performed (Table 2) . Among the 17 patients with aortic and mitral valve surgery, five needed aorto-mitral fibrous continuity reconstruction with bovine pericardium. The mean bypass time was 190 AE 92 (range: 53-606) min and the mean cross-clamp time was 128 AE 70 (range: 28-414) min.
Seventy-six patients (95.0%) underwent ultrafiltration during the operation. Of these 76 patients, the mean volume of fluid removed by conventional ultrafiltration (n = 75) and modified ultrafiltration (n = 64) was 2672 AE 1319 and 1077 AE 408 ml, respectively. The average filtrated volume per body weight was 64 AE 29 (range: 18-147) ml kg À1 . The mean decreased body weight was 1.9 AE 1.6 kg immediately after surgery.
Patient follow-up
Compliance with follow-up was 100% in all survivors, with a mean duration of 56 AE 37 (range: 0-158) months. Valverelated complications were defined in accordance with the guidelines established by the American Association for Thoracic Surgery and the Society of Thoracic Surgeons [7] .
Statistical analysis
All measurements are expressed as the mean AE standard deviation. To determine the risk factors of long ventilator support time, univariate and multivariate analysis were performed using linear regression analysis after inverse transformation, because it was not normally distributed. To determine risk factors of late deaths, univariate and multivariate analysis were performed using Cox regression. Survival and event-free survival were determined using the Kaplan-Meier method. Differences between survival curves were determined using the log-rank test. A p value <0.05 was considered to be statistically significant. All statistical analyses were performed using SPSS (version 13.0, SPSS Inc., Chicago, IL, USA).
Results

Early mortality and morbidity
No patient died from cardiac failure. There was one hospital death (1.4%) due to septic shock in the patient with endocarditis and multiple interventricular septal abscesses.
Early morbidities are listed in Table 3 . Permanent pacemaker insertion was need in four patients because of complete atrioventricular block (n = 3) or sinus node dysfunction (n = 1). The mean postoperative ventilator support time was 66 AE 126 (range: 11-768) h. In 14 patients, ventilator support was needed >72 h and in four patients tracheostomy was needed due to difficulty in weaning from the ventilator. Univariate analysis of risk factors for prolonged ventilator support included age, preoperative NYHA functional class IV, preoperative presence of ascites, preoperative value of left ventricular ejection fraction, cardiopulmonary time and postoperative low cardiac output. Based on multivariate analysis, age ( p < 0.001) and the cardiopulmonary time ( p = 0.004) were identified as risk factors and preoperative left ventricular ejection fraction ( p = 0.098) were identified as marginally significant risk factors (Table 4) .
Late outcomes
During the follow-up period, there were seven deaths (8.8%). Five deaths were of cardiac causes, such as heart failure (n = 4) and infective endocarditis (n = 1). One patient died because of liver cirrhosis and chronic renal failure. The remaining one patient died suddenly. Kaplan-Meier survival at 5 and 8 years was 95 AE 3% and 79 AE 9%, respectively ( (Table 4) .
Tricuspid valve thrombosis occurred in five patients. In two patients, repeated valve thromboses occurred on two or three occasions. The linearised incidences of valve thrombosis were 1.3% per patient-year for all patients and 1.6% per patient-year for the patients with mechanical valves. In all the patients valve thrombolysis using urokinase was intended initially, but in two patients, re-operation of the tricuspid valve was needed. Another two patients needed subsequent cardiac surgery rather than tricuspid valve surgery such as heart transplantation and the Bentall operation. Cerebral haemorrhages occurred in three patients. The Kaplan-Meier event-free survival at 5 and 8 years was 76 AE 6% and 61 AE 9%, respectively (Fig. 2) . ECMO, extracorporeal membrane oxygenation; CVA, cerebrovascular accident; IABP, intra-aortic balloon pump.
Mechanical versus bioprosthetic valves
Mechanical prostheses were used in 62 cases. The mean age of the patients was 45.2 AE 11.8 (range: 21-69) years. All the mechanical prostheses were bi-leaflet valves and the size of the prostheses used ranged from 25 to 33 mm, the preferred sizes were 31 (n = 21) and 33 mm (n = 16). Bioprosthetic valves were used in 18 cases. The mean age of the patients was 60.7 AE 10.8 (range: 23-70) years. The size of the bioprostheses ranged from 27 to 33 mm, the preferred size was 31 mm (n = 15).
Survival and event-free survival were compared based on the type of prosthesis. The 5-year survival was 96 AE 3% in the mechanical group and 89 AE 7% in the bioprosthetic group ( p = 0.031; Fig. 3 ). The 5-year eventfree survival was 77 AE 6% in the mechanical group and 78 AE 10% in the bioprosthesis group. There was no difference in event-free survival between the two groups ( p = 0.322; Fig. 4 ).
Discussion
The current study included all the patients who underwent TVR during the study period. The only exceptional disease category was corrected transposition of the great arteries. In spite of co-morbidities, our patients had relatively favourable operative results. We did not know the precise reason(s) our patients had favourable operative results; however, we have attempted to offer some reasonable explanations.
First, our patient population was younger than the patients which comprised other studies [2] [3] [4] . The mean age of our patients was 48.7 AE 13.2 years, while the mean age of the other patients was >50 years. Second, improved myocardial protection strategies and perioperative care may have had a partial impact [2, 5, 6] . Multiple valve procedures need long aortic cross-clamping times, which may cause ischaemic damage of the heart. Long ischaemic time itself may not be a risk factor for early mortality in the current era. Third, we used as large prosthesis as possible so as not to create an unnecessarily high transvalvular pressure gradient [8] . High transvalvular pressure gradients can cause unnecessarily high central venous pressures and can lead to persistent right heart failure symptoms. Some might argue that large prosthesis could cause atrioventricular block. However, most patients already had dilated tricuspid annulus, so it is not difficult to implant larger size valves.
However, these possible causes do not satisfactorily explain the early favourable results. In spite of poor scientific proof, we speculated that modified ultrafiltration may play an important role [9] . The positive effect of modified ultrafiltration was proposed by Naik et al. in 1991 [10] and was verified by the findings in a prospective, randomised study in paediatric patients [11] , but not in adult cardiac surgery, especially on right ventricular function. By decreasing myocardial oedema, improving left ventricular function [12, 13] and improving pulmonary function compliance [11, 14, 15] , modified ultrafiltration could improve right ventricular function as well. With the exception of a few early cases, we routinely use modified ultrafiltration. We aggressively perform modified ultrafiltration, especially in the patients with heart failure with excess body water and decreased lung compliance.
Owing to improvements in the early outcomes of TVR in our institution, we performed TVR with less hesitation than previously. This factor further improved our early results too.
However, it is difficult to know the optimal timing of TVR. Early surgery might improve early outcomes, but produce valve-related complications thereafter. The 5-and 8-year survival and event-free survival rates of our patients were slightly better than of the results of others [1] [2] [3] [4] , but not satisfactory. Right ventricular function is known as a determinant of clinical symptoms, exercise capacity, perioperative survival and postoperative outcomes [16, 17] . Some patients had end-organ disease before TVR, such as liver cirrhosis, which could not be reversed completely after surgery. These factors make suboptimal follow-up results. To improve the long-term follow-up results, defining the optimal timing of surgery is necessary.
In conclusion, although TVR had a high incidence of postoperative morbidity because of re-do operations, combined left-sided valve surgery, right heart failure and concomitant liver disease, the operative outcome can be improved in the current era through improvement in myocardial protection, perioperative care and the modified ultrafiltration. It is not wise to delay TVR because of the potential high operative mortality rate. Although there is no universal agreement about the optimal timing of TVR, it is our opinion that it is better to perform TVR early so as not to develop irreversible right ventricular failure with end-organ failure. There should be additional studies to define the optimal timing of TVR.
